Twelve Republican Senators Support Grassley-Wyden Drug Pricing Bill
As of Feb. 18, Senate Finance Chairman Chuck Grassley (R-IA) and Ranking Member Ron Wyden’s (D-OR) bipartisan drug pricing legislation now has 12 Republican senators in support of the plan. Sen. Grassley said he needs support from at least 25 Republican senators to convince Senate Majority Leader Mitch McConnell (R-KY) to bring S. 2543 to the Senate floor for a vote. The senators who have said they support the legislation, however, have not officially cosponsored the legislation.


FDA, FTC Collaborate to End Biosimilars Misinformation and Increase Competition
On Feb. 3, the Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) announced a collaboration to advance biosimilars adoption, discourage false or misleading communications about biosimilars and deter anticompetitive behaviors.

To begin, a public meeting will be held on March 9, 2020, for input on how to increase competition for biological products.

Find the statement here.

Read more on healthcare policy on the McGuireWoods Consulting website.